What is Guardant360®?

The Guardant360® assay is Guardant Health's breakthrough liquid biopsy for cancer patients with advanced solid tumors. This test is done using circulating tumor DNA (ctDNA), which is produced when tumors shed small pieces of their genetic material into the bloodstream. Traces of this ctDNA can be detected in the blood using our digital sequencing technology.

Over 70 clinically-relevant genes are examined in the Guardant360® test to identify genomic alterations within your cancer's DNA. This helps your physician understand which alterations exist in your cancer without the complications and delays of a tissue biopsy. As a result, physicians are able to see the most current genomic profile of your tumor and recommend appropriate treatment.

Why choose Guardant360®?

Simple and Safe

- Requires only two tubes of blood for testing (10ml each)
- Non-invasive liquid biopsy for advanced solid tumors
- Avoid the complications and delays of invasive tissue biopsies
- A safer alternative to repeat tissue biopsies

Quick and Accurate

- Turnaround time of approximately seven days for the blood test results upon receipt in the US laboratory, making quick treatment decisions a reality
- 90% agreement with tissue[1] for targetable alterations, making this a feasible alternative to pick up actionable tumor mutations missed during tissue biopsies
- Detects all four classes of genomic variations in 70+ genes most relevant to solid tumors and microsatellite instability-high (MSI-high)
- Comprehensive testing for targeted therapy options

REFERENCE: 1. Leighl NB et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. 2019

Is Guardant360® right for you?

Used by Leading Oncologists

ordered by over
6,000
oncologists worldwide

backed by over
100,000
clinical samples

validated by over
100
peer-reviewed publications

YES, if you are an:

- Advanced stage cancer patient with a solid tumor, whose tissue biopsy is insufficient for genetic testing
- Advanced stage cancer patient who wants to identify targeted therapy options while avoiding an invasive repeat tissue biopsy

NO, if you have:

- Early stage cancer
- A cancer that is stable or responding to therapy
- Blood cancer / hematologic malignancy